Lexeo Therapeutics, Inc. Earnings Per Share Disclosure
9. Net Loss per Share
Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:
|
Year Ended |
|
|||||
|
December 31, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Numerator: |
|
|
|
|
|
||
Net loss attributable to common stockholders |
$ |
(99,961 |
) |
|
$ |
(98,333 |
) |
Denominator: |
|
|
|
|
|
||
Weighted-average common shares outstanding, basic and diluted |
|
53,645,323 |
|
|
|
31,787,491 |
|
Net loss per share attributable to common stockholders, basic and diluted |
$ |
(1.86 |
) |
|
$ |
(3.09 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
| 2023 | Mar 11, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.